Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary ...

Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary ...

Primary sclerosing cholangitis is a rare liver complication that can develop among people with inflammatory bowel disease. Early diagnosis can help, but there’s no cure.

Primary sclerosing cholangitis is a rare, unpreventable liver complication that can happen among people with inflammatory bowel disease.

Topline data were announced from a phase 2b/3 trial evaluating saroglitazar in patients with PBC who had an inadequate response or intolerance to UDCA.

1 Texas Liver Institute, University of Texas Health San Antonio, San Antonio, USA 2 National Institute for Health Research Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal ...

Discover a study exploring how verbal instructions and symptom expectations influence fatigue and motivation in people living with primary biliary cholangitis.

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is ...

If you are living with long-lasting or “chronic” pain, you are not alone. About 100,000,000 Americans are living with chronic pain or pain that lasts for a long time. Chronic pain can be debilitating ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. In The Lancet, the results ...